Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Operating Margin (2016 - 2026)

Ani Pharmaceuticals' Operating Margin history spans 14 years, with the latest figure at 14.07% for Q4 2025.

  • On a quarterly basis, Operating Margin rose 1637.0% to 14.07% in Q4 2025 year-over-year; TTM through Dec 2025 was 12.58%, a 1248.0% increase, with the full-year FY2025 number at 12.58%, up 1248.0% from a year prior.
  • Operating Margin hit 14.07% in Q4 2025 for Ani Pharmaceuticals, down from 15.91% in the prior quarter.
  • Over the last five years, Operating Margin for ANIP hit a ceiling of 27.19% in Q1 2021 and a floor of 38.94% in Q4 2021.
  • Historically, Operating Margin has averaged 0.55% across 5 years, with a median of 4.43% in 2024.
  • Biggest five-year swings in Operating Margin: surged 4294bps in 2021 and later plummeted -5696bps in 2022.
  • Tracing ANIP's Operating Margin over 5 years: stood at 38.94% in 2021, then surged by 105bps to 1.93% in 2022, then soared by 165bps to 5.11% in 2023, then plummeted by -145bps to 2.3% in 2024, then skyrocketed by 713bps to 14.07% in 2025.
  • Business Quant data shows Operating Margin for ANIP at 14.07% in Q4 2025, 15.91% in Q3 2025, and 6.57% in Q2 2025.